4.8 Review

Th17: An effector CD4 T cell lineage with regulatory T cell ties

Journal

IMMUNITY
Volume 24, Issue 6, Pages 677-688

Publisher

CELL PRESS
DOI: 10.1016/j.immuni.2006.06.002

Keywords

-

Categories

Funding

  1. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI035783, R01AI035783, R01AI057956] Funding Source: NIH RePORTER
  2. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064400] Funding Source: NIH RePORTER
  3. NIAID NIH HHS [AI57956, AI35783] Funding Source: Medline
  4. NIDDK NIH HHS [DK64400] Funding Source: Medline

Ask authors/readers for more resources

The naive CD4 T cell is a multipotential precursor with defined antigen recognition specificity but substantial plasticity for development down distinct effector or regulatory lineages, contingent upon signals from cells of the innate immune system. The range of identified effector CD4 T cell lineages has recently expanded with description of an IL-17-producing subset, called Th17, which develops; via cytokine signals distinct from, and antagonized by, products of the Th1 and Th2 lineages. Remarkably, Th17 development depends on the pleiotropic cytokine TGF-beta, which is also linked to regulatory T cell development and function, providing a unique mechanism for matching CD4 T cell effector and regulatory lineage specification. Here, we review Th17 lineage development, emphasizing similarities and differences with established effector and regulatory T cell developmental programs that have important implications for immune regulation, immune pathogenesis, and host defense.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available